AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Genes & Diseases Article
PDF (712.7 KB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Rapid Communication | Open Access

PD-L1 expression and smoke exposure as biomarkers for optimizing adjuvant therapy for patients with resected limited-stage small-cell lung carcinoma

Chengming Liua,b,1, Zhanyu Wanga,b,1, Qingpeng Zenga,1, Sufei Zhenga,b, Xiaoli Fengc, Qi Xuea, Nan Suna,b ( ), Jie Hea,b,2 ( )
Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

1These authors contributed equally to this study.

2Jie He will handle correspondence at all stages of refereeing and publication, also post-publication.

Show Author Information

References

1

Rudin CM, Brambilla E, Faivre-Finn C, et al. Small-cell lung cancer. Nat Rev Dis Primers. 2021;7(1): 3
Crossref Google Scholar
2

Yan F, Pang J, Peng Y, et al. Elevated cellular PD1/PD-L1 expression confers acquired resistance to cisplatin in small cell lung cancer cells. PLoS One. 2016;11(9): e0162925
Crossref Google Scholar
3

Liu C, Zheng S, Jin R, et al. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity. Cancer Lett. 2020;470: 95-105
Crossref Google Scholar
4

Memmott RM, Wolfe AR, Carbone DP, et al. Predictors of response, progression-free survival, and overall survival in patients with lung cancer treated with immune checkpoint inhibitors. J Thorac Oncol. 2021;16(7): 1086-1098
Crossref Google Scholar
5

Zhou F, Zhao W, Gong X, et al. Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer. J Immunother Cancer. 2020;8(2): e001300
Crossref Google Scholar
Genes & Diseases
Volume 10 Issue 1,
January 2023
Pages 48-50
DOI: 10.1016/j.gendis.2022.02.017
Cite this article:
Liu C, Wang Z, Zeng Q, et al. PD-L1 expression and smoke exposure as biomarkers for optimizing adjuvant therapy for patients with resected limited-stage small-cell lung carcinoma. Genes & Diseases, 2023, 10(1): 48-50. https://doi.org/10.1016/j.gendis.2022.02.017

256

Views

4

Downloads

0

Crossref

0

Web of Science

0

Scopus

0

CSCD

Altmetrics
Published: 31 March 2022
© 2022 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co., Ltd.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Return